BT-PROTAC

Overview

BT-PROTAC is a bioorthogonally activatable BRD4/ BRD3 PROTAC degrader prodrug. BT-PROTAC is inactive when present alone, but upon activation by tetrazine compounds, it promotes the degradation of BRD4 and BRD3 via the ubiquitin-proteasome system, inhibits c-Myc expression, activates caspase-3 , and induces apoptosis in breast cancer cells. BT-PROTAC can be used for breast cancer research. (Pink: BRD4 and BRD3 ligand ( HY-13030 ); Blue: VHL ligand ( HY-125845 ); Black: linker ( HY-140189 )).

Application

Products | Products > Disease Areas > Others | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Others | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Others | Products > Signaling Pathways > Caspase | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > Epigenetic Reader Domain | Products > Signaling Pathways > Drug Intermediate | Products > Signaling Pathways > c-Myc

Product Information

• Catalog No.: HY-155371
• CAS No.: 3032848-64-6
• Molecular Formula: C59H74ClN9O10S2
• Molecular Weight: 1168.86
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source